5 sample research posters across clinical branches — generated by QThesis AI
Dr. Kavitha Subramaniam¹, Dr. Nalini Devi¹, Dr. Rakesh Singh²
¹ Dept. of Obstetrics & Gynaecology, JIPMER, Puducherry · ² Dept. of Endocrinology
FOGSI Annual Conference 2025 — Federation of Obstetric & Gynaecological Societies of India
To compare maternal outcomes (glycaemic control, preeclampsia, caesarean rate) and foetal outcomes (birth weight, NICU admission, neonatal hypoglycaemia) between insulin and metformin therapy in GDM.
HbA1c 6.1 vs 6.4%
Both groups similar at term
Insulin 48% vs Metformin 38%
Metformin group lower
Insulin 22% vs Metformin 13%
Less neonatal hypoglycaemia
Insulin 20% vs Metformin 12%
Macrosomia less in metformin
Glycaemic control was comparable between insulin and metformin (HbA1c 6.1 vs 6.4%, p = 0.18). Metformin was associated with significantly lower caesarean section rate (38% vs 48%, p = 0.038), NICU admissions (13% vs 22%, p = 0.041), LGA neonates (12% vs 20%, p = 0.029), and neonatal hypoglycaemia.
Metformin achieves equivalent glycaemic control as insulin in GDM with significantly better maternal and foetal outcomes — lower caesarean rate, fewer NICU admissions, and less macrosomia. Metformin should be considered first-line pharmacotherapy for GDM in Indian obstetric practice.
Take-Home Message
Metformin matches insulin for blood sugar control but cuts C-section rates by 10% and NICU admissions by nearly half.
Generated with QThesis
AI-powered medical research platform
Poster 4 of 5 · Obstetrics & Gynaecology